Submitted:
07 September 2023
Posted:
11 September 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
Study Design
Study Populations
PCS Patients
CAD Patients
Ethical Approval
Exercise Training
Assessment of Perceived disease Burden, Functional status, and Fatigue
Cardiopulmonary Exercise Testing (CPET)
Laboratory Parameters
Statistical Analysis
3. Results
Disease Perception
Baseline Performance and Physical exercise Training
Effect of Training Modalities on Physical Exercise Capacity
Comparison of Medical Rehabilitation Effectivity on Physical Performance Improvement
4. Discussion
5. Conclusion
Digital Content
Authors Contributions
Data availability
Additional information
Supplementary Materials
Funding
Acknowledgments
Conflicts of Interest
References
- Koczulla AR, Ankermann T, Behrends U, Berlit P, Böing S, Brinkmann F, Franke C, Glöckl R, Gogoll C, Hummel T, Kronsbein J, Maibaum T, Peters EMJ, Pfeifer M, Platz T, Pletz M, Pongratz G, Powitz F, Rabe KF, Scheibenbogen C, Stallmach A, Stegbauer M, Wagner HO, Waller C, Wirtz H, Zeiher A, Zwick RH. S1-Leitlinie Post-COVID/Long-COVID [S1 Guideline Post-COVID/Long-COVID]. Pneumologie. 2021;75(11):869–900. ger. Cited in: PubMed; PMID 34474488. [CrossRef]
- Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A Review of Persistent Post-COVID Syndrome (PPCS). Clin Rev Allergy Immunol. 2023;64(1):66–74. Cited in: PubMed; PMID 33609255. [CrossRef]
- Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15. Cited in: PubMed; PMID 33753937. [CrossRef]
- Rabady S, Altenberger J, Brose M, Denk-Linnert D-M, Fertl E, Götzinger F, La Cruz Gomez Pellin M de, Hofbaur B, Hoffmann K, Hoffmann-Dorninger R, Koczulla R, Lammel O, Lamprecht B, Löffler-Ragg J, Müller CA, Poggenburg S, Rittmannsberger H, Sator P, Strenger V, Vonbank K, Wancata J, Weber T, Weber J, Weiss G, Wendler M, Zwick R-H. Leitlinie S1: Long COVID: Differenzialdiagnostik und Behandlungsstrategien [Guideline S1: Long COVID: Diagnostics and treatment strategies]. Wien Klin Wochenschr. 2021;133(Suppl 7):237–78. ger. Cited in: PubMed; PMID 34851455. [CrossRef]
- Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e107. Cited in: PubMed; PMID 34951953. [CrossRef]
- Serviente C, Decker ST, Layec G. From heart to muscle: pathophysiological mechanisms underlying long-term physical sequelae from SARS-CoV-2 infection. J Appl Physiol (1985). 2022;132(3):581–92. Cited in: PubMed; PMID 35019775. [CrossRef]
- Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263–4. Cited in: PubMed; PMID 35717982. [CrossRef]
- Nittas V, Gao M, West EA, Ballouz T, Menges D, Wulf Hanson S, Puhan MA. Long COVID Through a Public Health Lens: An Umbrella Review. Public Health Rev. 2022;431604501. Cited in: PubMed; PMID 35359614. [CrossRef]
- Garvey C, Bayles MP, Hamm LF, Hill K, Holland A, Limberg TM, Spruit MA. Pulmonary Rehabilitation Exercise Prescription in Chronic Obstructive Pulmonary Disease: Review of Selected Guidelines: AN OFFICIAL STATEMENT FROM THE AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY REHABILITATION. J Cardiopulm Rehabil Prev. 2016;36(2):75–83. Cited in: PubMed; PMID 26906147. [CrossRef]
- Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, Collet J-P, Corrado D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A, Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17–96. Cited in: PubMed; PMID 32860412. [CrossRef]
- Barbara C, Clavario P, Marzo V de, Lotti R, Guglielmi G, Porcile A, Russo C, Griffo R, Mäkikallio T, Hautala AJ, Porto I. Effects of exercise rehabilitation in patients with long coronavirus disease 2019. Eur J Prev Cardiol. 2022;29(7):e258-e260. Cited in: PubMed; PMID 35078233. [CrossRef]
- Jimeno-Almazán A, Pallarés JG, Buendía-Romero Á, Martínez-Cava A, Franco-López F, Sánchez-Alcaraz Martínez BJ, Bernal-Morel E, Courel-Ibáñez J. Post-COVID-19 Syndrome and the Potential Benefits of Exercise. Int J Environ Res Public Health. 2021;18(10). Cited in: PubMed; PMID 34067776. [CrossRef]
- Sawyer A, Cavalheri V, Hill K. Effects of high intensity interval training on exercise capacity in people with chronic pulmonary conditions: a narrative review. BMC Sports Sci Med Rehabil. 2020;1222. Cited in: PubMed; PMID 32257221. [CrossRef]
- Arena R, Myers J, Forman DE, Lavie CJ, Guazzi M. Should high-intensity-aerobic interval training become the clinical standard in heart failure? Heart Fail Rev. 2013;18(1):95–105. Cited in: PubMed; PMID 22791516. [CrossRef]
- Haykowsky MJ, Timmons MP, Kruger C, McNeely M, Taylor DA, Clark AM. Meta-analysis of aerobic interval training on exercise capacity and systolic function in patients with heart failure and reduced ejection fractions. Am J Cardiol. 2013;111(10):1466–9. Cited in: PubMed; PMID 23433767. [CrossRef]
- Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, Pieske-Kraigher E, Beckers P, Bobenko A, Hommel J, van de Heyning CM, Esefeld K, Korn P v., Christle JW, Haykowsky MJ, Linke A, Wisløff U, Adams V, Pieske B, van Craenenbroeck EM, Halle M. Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2021;325(6):542–51. Cited in: PubMed; PMID 33560320. [CrossRef]
- Adolfo JR, Dhein W, Sbruzzi G. Intensity of physical exercise and its effect on functional capacity in COPD: systematic review and meta-analysis. J Bras Pneumol. 2019;45(6):e20180011. Cited in: PubMed; PMID 31576905. [CrossRef]
- Beauchamp MK, Nonoyama M, Goldstein RS, Hill K, Dolmage TE, Mathur S, Brooks D. Interval versus continuous training in individuals with chronic obstructive pulmonary disease--a systematic review. Thorax. 2010;65(2):157–64. Cited in: PubMed; PMID 19996334. [CrossRef]
- Keech A, Way K, Holgate K, Fildes J, Indraratna P, Yu J. HIIT for post-COVID patients within cardiac rehabilitation: Response to letter to the editor. Int J Cardiol. 2021;322291–2. Cited in: PubMed; PMID 32882289. [CrossRef]
- Smets EM, Garssen B, Bonke B, Haes JC de. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–25. Cited in: PubMed; PMID 7636775. [CrossRef]
- Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83. Cited in: PubMed; PMID 1593914.
- Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167–76. Cited in: PubMed; PMID 25831962. [CrossRef]
- Ilmarinen J, Tempel J. Erhaltung, Förderung und Entwicklung der Arbeitsfähigkeit: Konzepte und Forschungsergebnisse aus Finnland. In: Badura B, Schellschmidt H, Vetter C, editors. Fehlzeiten-Report 2002, Demographischer Wandel: Herausforderung für die betriebliche Personal-und Gesundheitspolitik. Berlin: Springer; 2003.
- Dowman LM, May AK, Hill CJ, Bondarenko J, Spencer L, Morris NR, Alison JA, Walsh J, Goh NSL, Corte T, Glaspole I, Chambers DC, McDonald CF, Holland AE. High intensity interval training versus moderate intensity continuous training for people with interstitial lung disease: protocol for a randomised controlled trial. BMC Pulm Med. 2021;21(1):361. Cited in: PubMed; PMID 34758808. [CrossRef]
- Schmitz B, Niehues H, Thorwesten L, Klose A, Krüger M, Brand S-M. Sex Differences in High-Intensity Interval Training–Are HIIT Protocols Interchangeable Between Females and Males? Front Physiol. 2020;11. Cited in: PubMed; PMID 32063866. [CrossRef]
- Sainani, KL. Dealing With Missing Data. PM R. 2015;7(9):990–4. Cited in: PubMed; PMID 26388026. [CrossRef]
- Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, Possick JD, Systrom DM, Waxman AB. Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing. Chest. 2022;161(1):54–63. Cited in: PubMed; PMID 34389297. [CrossRef]
- Clavario P, Marzo V de, Lotti R, Barbara C, Porcile A, Russo C, Beccaria F, Bonavia M, Bottaro LC, Caltabellotta M, Chioni F, Santangelo M, Hautala AJ, Griffo R, Parati G, Corrà U, Porto I. Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up. Int J Cardiol. 2021;340113–8. Cited in: PubMed; PMID 34311011. [CrossRef]
- Jimeno-Almazán A, Franco-López F, Buendía-Romero Á, Martínez-Cava A, Sánchez-Agar JA, Sánchez-Alcaraz Martínez BJ, Courel-Ibáñez J, Pallarés JG. Rehabilitation for post-COVID-19 condition through a supervised exercise intervention: A randomized controlled trial. Scand J Med Sci Sports. 2022;32(12):1791–801. Cited in: PubMed; PMID 36111386. [CrossRef]
- Ostrowska M, Rzepka-Cholasińska A, Pietrzykowski Ł, Michalski P, Kosobucka-Ozdoba A, Jasiewicz M, Kasprzak M, Kryś J, Kubica A. Effects of Multidisciplinary Rehabilitation Program in Patients with Long COVID-19: Post-COVID-19 Rehabilitation (PCR SIRIO 8) Study. J Clin Med. 2023;12(2). Cited in: PubMed; PMID 36675349. [CrossRef]
- Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, Völler H, Davos CH. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: The avenue towards EAPC accreditation programme: A position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2020. Cited in: PubMed; PMID 33611459. [CrossRef]
- Hanakam F, Ferrauti A. Ausdauertraining. In: Ferrauti A, editor. Trainingswissenschaft für die Sportpraxis, Lehrbuch für Studium, Ausbildung und Unterricht im Sport. Berlin, Heidelberg: Springer Berlin Heidelberg; 2020. p. 345–404.



| Overall (n=110) |
IT (n=45) |
CT (n=65) |
p-value | |
|---|---|---|---|---|
| Anthropometric data | ||||
| Age, years | 49.3 ± 11.8 | 50.5 ± 10.1 | 48.4 ± 12.8 | 0.359 |
| Sex, n (%) | 0.693 | |||
| female | 42 (38.2) | 16 (35.6) | 26 (40.0) | |
| male | 68 (61.8) | 29 (64.4) | 39 (60.0) | |
| Height, cm | 174.6 ± 9.5 | 174.5 ± 9.2 | 174.7 ± 9.7 | 0.924 |
| Weight, kg | 92.5 ± 21.0 | 93.3 ± 18.2 | 91.9 ± 22.8 | 0.372 |
| BMI, kg*m-2 | 30.2 ± 6.0 | 30.6 ± 5.7 | 29.9 ± 6.2 | 0.270 |
| Clinical data | ||||
| Diseases of the circulatory system, n (%) | 72 (65.6) | 29 (64.4) | 43 (66.2) | 0.855 |
| Arterial hypertension | 55 (50) | 22 (48.9) | 33 (50.8) | 0.848 |
| Pulmonary embolism | 10 (9.1) | 4 (8.9) | 6 (9.2) | 0.952 |
| Paroxysmal tachycardia | 15 (13.6) | 4 (8.9) | 11 (16.9) | 0.231 |
| Coronary artery disease | 3 (2.7) | 2 (4.4) | 1 (1.5) | 0.405 |
| Other | 23 (20.9) | 8 (17.8) | 15 (23.1) | 0.506 |
| Endocrine, nutritional or metabolic diseases, n (%) | 73 (66.4) | 31 (68.9) | 42 (64.6) | 0.645 |
| Obesity | 57 (51.8) | 26 (57.8) | 31 (47.7) | 0.302 |
| Type 2 diabetes mellitus | 12 (10.9) | 3 (6.7) | 9 (13.8) | 0.239 |
| Hypothyroidism, n (%) | 11 (10.0) | 3 (6.7) | 8 (12.3) | 0.337 |
| Other | 25 (22.7) | 8 (17.8) | 17 (26.2) | 0.307 |
| Diseases of the musculoskeletal system and connective tissue, n (%) | 43 (39.1) | 12 (26.7) | 31 (47.7) | 0.026* |
| Diseases of the nervous system, n (%) | 28 (25.5) | 13 (28.9) | 15 (23.1) | 0.502 |
| Migraine/ headache | 3 (2.7) | 1 (2.2) | 2 (3.1) | 0.789 |
| Other | 25 (22.7) | 12 (26.7) | 13 (20.0) | 0.426 |
| Mental and behavioral disorders, n (%) | 28 (25.5) | 13 (28.9) | 15 (23.1) | 0.502 |
| Depressive/ adjustment disorders | 19 (17.3) | 9 (20.0) | 10 (15.4) | 0.542 |
| Other | 10 (9.1) | 4 (8.9) | 6 (9.2) | 0.952 |
| Diseases of the respiratory system, n (%) | 15 (13.6) | 8 (17.8) | 7 (10.8) | 0.316 |
| Diseases of the digestive system, n (%) | 14 (12.7) | 5 (11.1) | 9 (13.8) | 0.676 |
| Neoplasms, n (%) | 7 (6.4) | 2 (4.4) | 5 (7.7) | 0.497 |
| Medication | ||||
| ACE inhibitor | 19 (17.3) | 8 (17.8) | 11 (16.9) | 0.909 |
| Statin | 20 (18.2) | 8 (17.8) | 12 (18.5) | 0.928 |
| Beta blocker | 40 (36.4) | 16 (35.6) | 24 (36.9) | 0.885 |
| AT-II receptor blocker | 24 (21.8) | 11 (24.4) | 13 (20.0) | 0.588 |
| Calcium channel blocker | 21 (19.1) | 11 (24.4) | 10 (15.4) | 0.254 |
| Anticoagulant | 22 (20.0) | 8 (17.8) | 14 (21.5) | 0.632 |
| Antiarrhythmic | 1 (0.9) | 0 (0) | 1 (1.5) | 0.408 |
| Diuretic | 22 (20.0) | 12 (26.7) | 10 (15.4) | 0.165 |
| Glucocorticoid | 18 (16.4) | 7 (15.6) | 11 (16.9) | 0.851 |
| Analgesic | 26 (23.6) | 10 (22.2) | 16 (24.6) | 0.774 |
| Antidepressant | 15 (13.6) | 7 (15.6) | 8 (12.3) | 0.636 |
| Diabetes medication | 6 (5.5) | 1 (2.2) | 5 (7.7) | 0.218 |
| Blood Parameters | ||||
| Leukocytes, n/nl | 6.9 ± 1.8 | 7.0 ± 1.8 | 6.8 ± 1.9 | 0.674 |
| Erythrocytes, M/µl | 4.9 ± 0.4 | 4.9 ± 0.4 | 4.9 ± 0.5 | 0.847 |
| Red cell distribution width (RDW), % | 13.1 ± 0.9 | 13.1 ± 0.7 | 13.2 ± 1.1 | 0.568 |
| Hemoglobin, g/dl | 14.5 ± 1.4 | 14.7 ± 1.2 | 14.4 ± 1.5 | 0.314 |
| Hematocrit, % | 43.6 ± 3.8 | 44.0 ± 3.3 | 43.3 ± 4.1 | 0.368 |
| Mean corpuscular volume (MCV), fl | 90.0 ± 5.3 | 90.6 ± 3.2 | 89.7 ± 6.3 | 0.407 |
| Mean corpuscular hemoglobin (MCH), pg | 30.0 ± 2.1 | 30.2 ± 1.1 | 29.8 ± 2.5 | 0.330 |
| Mean cellular hemoglobin concentration (MCHC), g/dl | 33.3 ± 1.1 | 33.4 ± 0.8 | 33.2 ± 1.2 | 0.474 |
| Thrombocytes, n/nl | 254.6 ± 67.1 | 261.1 ± 54.0 | 250.2 ± 74.8 | 0.402 |
| HbA1c, % | 6.1 ± 0.8 | 6.1 ± 0.7 | 6.0 ± 0.9 | 0.891 |
| C-reactive protein, mg/dl | 0.4 ± 0.6 | 0.3 ± 0.3 | 0.4 ± 0.7 | 0.424 |
| Sodium, mmol/l | 141.0 ± 2.1 | 141.5 ± 2.2 | 140.6 ± 2.1 | 0.023* |
| Potassium, mmol/l | 4.3 ± 0.4 | 4.3 ± 0.4 | 4.3 ± 0.4 | 0.401 |
| Creatinin, mg/dl | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.8 ± 0.2 | 0.438 |
| Urea, mg/dl | 30.5 ± 8.0 | 30.4 ± 7.2 | 30.6 ± 8.5 | 0.882 |
| eGFR, ml/min/1.73qm | 95.5 ± 15.0 | 93.7 ± 15.0 | 96.8 ± 15.1 | 0.305 |
| Uric acid, mg/dl | 5.9 ± 1.5 | 6.1 ± 1.4 | 5.7 ± 1.5 | 0.100 |
| Triglycerides, mg/dl | 166.7 ± 112.0 | 169.0 ± 89.6 | 165.1 ± 125.8 | 0.858 |
| Cholesterol, mg/dl | 207.5 ± 49.4 | 207.6 ± 60.0 | 207.5 ± 41.0 | 0.989 |
| HDL cholesterol, mg/dl | 55.1 ± 16.7 | 55.3 ± 17.8 | 55.1 ± 16.0 | 0.947 |
| LDL cholesterol, mg/dl | 134.0 ± 43.5 | 136.5 ± 52.7 | 132.2 ± 36.1 | 0.635 |
| LDL/HDL ratio | 2.6 ± 1.0 | 2.6 ± 0.9 | 2.6 ± 1.1 | 0.890 |
| Creatin kinase, U/l | 159.2 ± 125.7 | 163.2 ± 110.6 | 156.6 ± 135.7 | 0.789 |
| Glutamate oxalacetate transaminase (GOT), U/l | 32.6 ± 13.1 | 34.2 ± 15.7 | 31.6 ± 12.0 | 0.322 |
| Glutamate pyruvate transaminase (GPT), U/l | 39.7 ± 23.1 | 42.1 ± 19.9 | 38.0 ± 25.1 | 0.370 |
| Gamma glutamyl transferase (gamma GT), U/l | 38.9 ± 26.5 | 45.0 ± 32.8 | 34.8 ± 20.5 | 0.071 |
| Alkaline phosphatase, U/l | 79.4 ± 25.5 | 77.8 ± 23.1 | 80.4 ± 27.1 | 0.599 |
| Thyroid stimulating hormone (TSH), mlU/l | 1.4 ± 0.8 | 1.5 ± 0.9 | 1.2 ± 0.6 | 0.164 |
| Overall (n=110) |
IT (n=45) |
CT (n=65) |
p-value | |
|---|---|---|---|---|
| Multidimensional fatigue inventory (MFI-20) | ||||
|
Overall Score T0 T1 Δ |
69.8 ± 13.2 58.6 ± 15.9 -11.3 ± 15.0*** |
68.2 ± 14.9 54.3 ± 14.6 -14.2 ± 12.6 |
70.9 ± 11.9 61.4 ± 16.1 -9.4 ± 16.3 |
0.339 0.029# 0.124 |
|
Physical Fatigue T0 T1 Δ |
77.2 ± 15.5 62.8 ± 19.2 -14.3 ± 20.5*** |
76.3 ± 16.8 57.7 ± 17.7 -19.1 ± 18.9 |
77.8 ± 14.1 66.1 ± 19.6 -11.3 ± 21.0 |
0.663 0.033# 0.062 |
|
Mental Fatigue T0 T1 Δ |
65.5 ± 20.0 57.0 ± 19.9 -9.1 ± 16.2*** |
64.3 ± 18.9 53.1 ± 18.8 -11.7 ± 14.9 |
66.3 ± 20.8 59.6 ± 20.2 -7.5 ± 16.9 |
0.621 0.112 0.212 |
| SF-36 Health-related quality of life | ||||
|
Physical Component Score (PCS) T0 T1 Δ |
30.4 ± 7.8 35.2 ± 9.1 4.6 ± 7.2*** |
31.3 ± 7.0 38.0 ± 8.8 6.9 ± 7.3 |
29.9 ± 8.3 33.4 ± 8.9 3.1 ± 6.7 |
0.366 0.015# 0.013# |
|
Mental Component Score (MCS) T0 T1 Δ |
35.7 ± 12.2 41.7 ± 11.5 6.0 ± 10.2*** |
36.5 ± 11.2 41.5 ± 11.6 6.0 ± 8.5 |
35.1 ± 12.9 41.9 ± 11.6 6.0 ± 11.2 |
0.573 0.852 0.984 |
| Wellbeing (WHO-5) T0 T1 Δ |
8 (22) 14 (24) 4 (26)*** |
8 (20) 15 (23) 5 (22) |
8 (18) 12.5 (22) 4 (26) |
0.356 0.126 0.301 |
| Hospital anxiety and depression scale (HADS) | ||||
|
Anxiety T0 T1 Δ |
7 (16) 6 (18) 0 (18)** |
8 (15) 6 (18) 0 (17) |
6.5 (16) 5.5 (15) 0 (18) |
0.190 0.935 0.628 |
|
Depression T0 T1 Δ |
7 (19) 5 (20) 0 (22)* |
8 (16) 5 (20) 0 (22) |
7 (19) 5 (20) 0 (17) |
0.640 0.681 0.710 |
| Workability Index(WAI)$ | 22.1 ± 7.4 | 23.7 ± 8.0 | 21.1 ± 6.8 | 0.104 |
| max. incapacity for work last 12 months§ | 99 (365) | 99 (365) | 99 (365) | 0.859 |
| Overall (n=110) |
IT (n=45) |
CT (n=65) |
p-value | |
|---|---|---|---|---|
| Resting | ||||
|
Heart rate, beat·min-1 T0 T1 Δ |
89.1 ± 11.5 83.3 ± 11.6 -6.0 ± 10.1*** |
88.3 ± 11.2 83.6 ± 11.1 -4.0 ± 9.7 |
89.7 ± 11.7 83.1 ± 12.0 -7.2 ± 10.2 |
0.545 0.820 0.126 |
|
O2 pulse, ml·beat-1 T0 T1 Δ |
6.8 ± 1.9 6.8 ± 1.6 -0.0 ± 1.5 |
6.8 ± 1.8 7.0 ± 1.4 0.2 ± 1.4 |
6.8 ± 1.9 6.6 ± 1.6 -0.2 ± 1.5 |
0.915 0.169 0.313 |
|
Ventilatory equivalent O2 (VE/VO2) T0 T1 Δ |
28.0 ± 5.9 28.2 ± 6.9 0.2 ± 7.3 |
27.0 ± 6.3 27.2 ± 4.9 0.2 ± 6.7 |
28.5 ± 5.6 29.0 ± 7.9 0.2 ± 7.7 |
0.210 0.218 0.982 |
|
Ventilatory equivalent CO2 (VE/VCO2) T0 T1 Δ |
33.9 ± 8.8 35.1 ± 9.7 1.0 ± 12.6 |
33.8 ± 12.5 33.4 ± 3.8 -0.5 ± 13.3 |
34.1 ± 5.0 36.2 ± 12.0 1.9 ± 12.2 |
0.880 0.162 0.367 |
| Ventilatory threshold 1 (VT1) | ||||
|
Workload, W (% predicted) T0 T1 Δ |
73.7 ± 27.1 (42.5 ± 14.9) 85.1 ± 25.0 (50.2 ± 15.7) 10.5 ± 20.1 (6.8 ± 12.1)*** |
73.5 ± 26.9 (42.3 ± 14.2) 84.9 ± 22.3 (50.6 ± 14.1) 10.4 ± 22.5 (6.8 ± 12.9) |
73.8 ± 27.4 (42.7 ± 15.5) 85.2 ± 27.0 (49.9 ± 16.9) 10.6 ± 18.3 (6.8 ± 11.5) |
0.887 0.821 0.998 |
|
Heart rate, beat·min-1 (% predicted) T0 T1 Δ |
109.3 ± 13.7 (65.4 ± 7.7) 106.6 ± 20.3 (64.2 ± 11.3) -3.8 ± 16.9 (-2.3 ± 10.6) |
107.4 ± 11.9 (64.7 ± 7.3) 105.5 ± 14.5 (64.3 ± 8.4) -1.5 ± 12.7 (-1.0 ± 7.7) |
110.6 ± 14.7 (65.9 ± 7.9) 107.3 ± 23.7 (64.1 ± 13.1) -5.4 ± 19.3 (-3.2 ± 12.2) |
0.429 0.945 0.318 |
|
O2 pulse, ml·beat-1 (% predicted) T0 T1 Δ |
10.6 ± 2.9 (77.2 ± 16.2) 11.3 ± 2.8 (83.5 ± 17.1) 0.7 ± 1.8 (5.5 ± 14.7)*** |
11.0 ± 2.8 (79.7 ± 17.3) 11.5 ± 2.4 (85.3 ± 16.0) 0.4 ± 1.3 (3.2 ± 8.9) |
10.3 ± 2.9 (75.5 ± 15.2) 11.2 ± 3.1 (82.2 ± 17.9) 1.0 ± 2.1 (7.2 ± 17.7) |
0.197 0.381 0.196 |
|
VO2, ml·min-1·kg-1 (% predicted) T0 T1 Δ |
12.4 ± 3.0 (50.5 ± 11.7) 13.2 ± 3.4 (54.6 ± 11.7) 0.8 ± 2.5 (3.1 ± 10.0)* |
12.5 ± 2.9 (51.4 ± 12.1) 12.8 ± 2.9 (54.7 ± 11.9) 0.3 ± 2.3 (1.4 ± 8.9) |
12.4 ± 3.1 (50.0 ± 11.5) 13.5 ± 3.7 (54.6 ± 11.6) 1.2 ± 2.7 (4.3 ± 10.6) |
0.534 0.941 0.164 |
|
Ventilatory equivalent O2 (VE/VO2) (% predicted) T0 T1 Δ |
27.4 ± 4.7 (78.3 ± 13.4) 26.6 ± 3.9 (75.9 ± 11.2) -0.8 ± 4.4 (-2.1 ± 12.5) |
27.1 ± 3.8 (77.3 ± 10.9) 26.7 ± 4.1 (76.3 ± 11.7) -0.4 ± 3.5 (-1.0 ± 10.1) |
27.6 ± 5.2 (79.0 ± 14.9) 26.5 ± 3.8 (75.7 ± 10.9) -1.0 ± 4.9 (-2.9 ± 14.0) |
0.541 0.771 0.486 |
|
Ventilatory equivalent CO2 (VE/VCO2) T0 T1 Δ |
30.6 ± 4.4 29.6 ± 3.8 -0.9 ± 3.3* |
30.0 ± 3.4 29.8 ± 3.6 -0.3 ± 2.6 |
31.0 ± 4.9 29.5 ± 3.9 -1.3 ± 3.7 |
0.223 0.687 0.121 |
| Peak exercise | ||||
|
Respiratory exchange rate (RER) (% predicted) T0 T1 Δ |
1.05 ± 0.1 (87.1 ± 7.7) 1.05 ± 0.1 (87.1 ± 6.4) 0.00 ± 0.1 (0.2 ± 6.3) |
1.06 ± 0.1 (87.3 ± 6.7) 1.06 ± 0.1 (87.4 ± 6.2) 0.00 ± 0.1 (0.0 ± 5.4) |
1.05 ± 0.1 (87.0 ± 8.3) 1.05 ± 0.1 (86.8 ± 6.6) -0.0 ± 0.1 (-0.4 ± 6.8) |
0.815 0.634 0.758 |
|
Workload, W (% predicted) T0 T1 Δ |
127.8 ± 38.5 (73.4 ± 21.1) 140.1 ± 39.2 (81.0 ± 24.6) 12.6 ± 18.3 (7.5 ± 15.0)*** |
130.2 ± 38.0 (74.1 ± 20.7) 142.5 ± 37.1 (84.2 ± 19.5) 11.6 ± 18.5 (8.7 ± 14.7) |
126.2 ± 39.0 (72.9 ± 21.5) 138.3 ± 40.9 (78.7 ± 27.8) 13.4 ± 18.4 (6.6 ± 15.3) |
0.775 0.283 0.507 |
|
Heart rate, beat·min-1 (% predicted) T0 T1 Δ |
135.3 ± 21.2 (80.9 ± 11.5) 132.2 ± 20.2 (79.6 ± 10.9) -2.6 ± 13.9 (-1.4 ± 8.5) |
134.2 ± 18.3 (80.7 ± 10.4) 129.7 ± 17.0 (79.0 ± 9.4) -3.3 ± 12.4 (-1.9 ± 7.6) |
136.1 ± 23.0 (81.0 ± 12.3) 134.0 ± 22.2 (80.1 ± 11.9) -2.2 ± 15.1 (-1.1 ± 9.1) |
0.890 0.645 0.642 |
|
O2 pulse, ml·beat-1 (% predicted) T0 T1 Δ |
12.7 ± 3.3 (92.6 ± 17.4) 13.3 ± 3.0 (97.9 ± 16.0) 0.6 ± 1.8 (4.6 ± 12.4)*** |
13.1 ± 3.3 (94.5 ± 18.4) 13.6 ± 2.8 (100.1 ± 17.2) 0.3 ± 1.6 (2.8 ± 11.5) |
12.4 ± 3.2 (91.4 ± 16.7) 13.1 ± 3.1 (96.3 ± 15.0) 0.8 ± 1.9 (5.9 ± 12.9) |
0.370 0.266 0.233 |
|
VO2, ml·min-1·kg-1 (% predicted) T0 T1 Δ |
18.3 ± 4.4 (74.4 ± 15.3) 18.9 ± 4.8 (77.8 ± 15.6) 0.8 ± 2.9 (2.7 ± 11.0)* |
18.5 ± 4.3 (75.7 ± 14.8) 18.7 ± 4.4 (78.8 ± 14.8) 0.2 ± 2.9 (0.8 ± 11.2) |
18.2 ± 4.5 (73.6 ± 15.7) 19.1 ± 5.2 (77.1 ± 16.3) 1.3 ± 2.9 (4.1 ± 10.8) |
0.482 0.592 0.157 |
|
Ventilatory equivalent O2 (VE/VO2) (% predicted) T0 T1 Δ |
33.8 ± 6.1 (96.5 ± 17.5) 33.1 ± 5.1 (94.4 ± 14.5) -0.6 ± 4.6 (-1.7 ± 13.1) |
33.6 ± 5.5 (96.0 ± 15.7) 33.3 ± 5.8 (95.1 ± 16.5) -0.3 ± 3.3 (-1.0 ± 9.5) |
33.9 ± 6.6 (96.8 ± 18.7) 32.9 ± 4.5 (93.9 ± 12.9) -0.8 ± 5.4 (-2.2 ± 15.3) |
0.826 0.699 0.658 |
|
Ventilatory equivalent CO2 (VE/VCO2) T0 T1 Δ |
32.1 ± 5.1 31.4 ± 4.3 -0.5 ± 3.6 |
31.8 ± 4.3 31.4 ± 4.5 -0.4 ± 2.5 |
32.3 ± 5.7 31.4 ± 4.1 -0.6 ± 4.2 |
0.601 0.942 0.733 |
|
Respiratory minute ventilation (VE), l·min-1 (% predicted) T0 T1 Δ |
60.3 ± 15.0 (58.0 ± 13.3) 60.9 ± 15.8 (59.0 ± 13.4) 0.9 ± 11.0 (1.3 ± 10.6) |
61.3 ± 14.1 (58.4 ± 12.2) 61.5 ± 14.8 (59.7 ± 13.0) -0.3 ± 10.4 (0.2 ± 9.7) |
59.6 ± 15.7 (57.8 ± 14.1) 60.4 ± 16.7 (58.4 ± 13.8) 1.7 ± 11.4 (2.0 ± 11.2) |
0.807 0.643 0.417 |
|
Tidal volume (Vt), l (% predicted) T0 T1 Δ |
2.1 ± 0.6 (72.4 ± 23.6) 2.2 ± 0.6 (74.4 ± 20.6) 0.1 ± 0.3 (2.1 ± 23.3) |
2.1 ± 0.5 (73.1 ± 21.1) 2.2 ± 0.6 (74.1 ± 19.2) 0.1 ± 0.3 (1.6 ± 21.9) |
2.1 ± 0.6 (71.9 ± 25.3) 2.2 ± 0.6 (74.7 ± 21.8) 0.1 ± 0.3 (2.4 ± 24.4) |
0.792 0.887 0.882 |
|
Breathing frequency (Bf), breaths·min-1 (% predicted) T0 T1 Δ |
30.1 ± 8.0 (54.7 ± 14.5) 29.1 ± 6.8 (53.0 ± 12.4) -0.6 ± 4.9 (-1.1 ± 8.8) |
29.9 ± 6.2 (54.4 ± 11.3) 29.4 ± 6.4 (53.5 ± 11.5) -1.1 ± 4.1 (-2.0 ± 7.2) |
30.2 ± 9.1 (54.9 ± 16.4) 28.9 ± 7.2 (52.6 ± 13.0) -0.3 ± 5.4 (-0.4 ± 9.7) |
0.874 0.729 0.386 |
|
Breathing reserve (BR), % T0 T1 Δ |
37.9 ± 19.5 37.6 ± 18.0 0.6 ± 15.9 |
36.1 ± 19.7 37.2 ± 18.0 3.5 ± 13.9 |
39.1 ± 19.4 37.9 ± 18.1 -1.5 ± 17.0 |
0.440 0.853 0.129 |
| Overall (n=110) |
IT (n=45) |
CT (n=65) |
p-value | |
|---|---|---|---|---|
| Sessions prescribed, n | 15 (20) | 16 (16) | 14 (20) | 0.125 |
| Sessions performed, % | 92.7 ± 10.7 | 89.5 ± 11.3 | 94.9 ± 9.6 | 0.012* |
| Workload Increase, % | 10.1 ± 10.5 | 9.6 ± 10.1 | 10.4 ± 10.9 | 0.695 |
| Exercise heart rate, beat·min-1 | 112.2 ± 14.8 | 113.9 ± 14.4 | 111.1 ± 15.0 | 0.317 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
